Insider Selling: Enfusion, Inc. (NYSE:ENFN) CFO Sells $17,598.84 in Stock

Enfusion, Inc. (NYSE:ENFN) CFO Bradley Herring sold 1,533 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $17,598.84. Following the completion of the sale, the chief financial officer now owns 329,334 shares of the company’s stock, valued at approximately $3,780,754.32. This trade represents a 0.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Bradley Herring also recently made the following trade(s):

• On Wednesday, March 5th, Bradley Herring sold 4,645 shares of Enfusion stock. The stock was sold at an average price of $11.38, for a total value of $52,860.10.
• On Wednesday, March 5th, Bradley Herring sold 4,645 shares of Enfusion stock. The shares were sold at an average price of $11.38, for a total value of $52,860.10.
• On Tuesday, January 7th, Bradley Herring sold 4,134 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total value of $41,877.42.
• On Friday, December 20th, Bradley Herring sold 24,443 shares of Enfusion stock. The shares were sold at an average price of $10.61, for a total value of $259,340.23.

Enfusion Trading Down 0.5 %

Shares of NYSE:ENFN opened at $11.24 on Friday. The stock has a fifty day simple moving average of $10.98 and a two-hundred day simple moving average of $9.88. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of 280.95, a PEG ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 12-month low of $7.83 and a 12-month high of $11.80.

Enfusion (NYSE:ENFN) last posted its earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The business had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. As a group, equities research analysts predict that Enfusion, Inc. will post 0.06 EPS for the current year.

Institutional Trading of Enfusion

Several large investors have recently modified their holdings of the company. Mackenzie Financial Corp grew its holdings in shares of Enfusion by 4.8% in the fourth quarter. Mackenzie Financial Corp now owns 31,271 shares of the company’s stock worth $322,000 after acquiring an additional 1,434 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Enfusion by 43.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 33,721 shares of the company’s stock worth $347,000 after acquiring an additional 10,173 shares during the period. Squarepoint Ops LLC grew its holdings in shares of Enfusion by 136.2% in the fourth quarter. Squarepoint Ops LLC now owns 35,633 shares of the company’s stock worth $367,000 after acquiring an additional 20,550 shares during the period. State of Wyoming grew its holdings in Enfusion by 52.7% during the fourth quarter. State of Wyoming now owns 76,814 shares of the company’s stock valued at $791,000 after purchasing an additional 26,525 shares during the period. Finally, Silvercrest Asset Management Group LLC bought a new stake in Enfusion during the fourth quarter valued at about $4,300,000. Institutional investors own 81.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ENFN shares. Stifel Nicolaus raised their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. William Blair restated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Piper Sandler raised their target price on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Enfusion has an average rating of “Hold” and an average price target of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.